Metastatic breast cancer (mBC) remains the leading cause of cancer-related death in women. Chemotherapy remains the backbone of mBC treatment; however, new developments across the therapeutic spectrum are expanding clinical approaches to care. Among chemotherapy agents, efforts are underway to improve delivery mechanisms, efficacy, and toxicity profiles, with a shift towards oral therapy, but how do we balance value, costs and health improvements?

® on December 17 at 3pm and 5 pm ET to gain insights from leaders from West Cancer Center and Stanford Cancer Centers as they discuss the shifting treatment paradigm in mBC and their approach to ensuring success with oral therapy.

Explore unmet treatment needs and innovations in mBC, particularly the developing spectrum of chemotherapeutic interventions

Educate the oncology community on emerging therapies in mBC with an emphasis on oral therapy

Discuss benefits and challenges of oral therapy, including the impact of COVID-19 on uptake

New Pathways and Chemotherapeutic Delivery Mechanisms in the Treatment of Metastatic Breast Cancer

When it comes to controlling health care spending, we need to allocate scarce resources based upon what brings the greatest value to patients and our health care system. Recent studies that examined health care improvements in life expectancy and patient well-being over 20 years found that spending in 2 areas often maligned for their costs—biopharmaceuticals and public health—account for much of those improvements. How do we balance value, costs and health improvements?

In this webinar, gain insights from leaders from National Pharmaceutical Council, Harvard University, and Blue Cross Blue Shield of Michigan as they discuss the studies and dive deeper into the implications of health spending on public health efforts and pharmaceuticals.


Interim President and CEO
National Pharmaceutical Council


Clinical Pharmacy Manager, Medicare Pharmacy Services
Blue Cross Blue Shield of Michigan


PhD Candidate, Program in Health Policy, Harvard University


Vice President of Research
National Pharmaceutical Council


Otto Eckstein Professor of Applied Economics
Harvard University

Bang for the Buck: How Health Care Innovation Affects Life Expectancy and Patient Well-Being

 welcomes leaders from Anthem and a partner of Anthem’s Doula Pilot Program in California, to discuss how a health plan can take an active role in 

 in maternity mortality, which has been recognized by the World Health Organization as a growing health concern in the United States.

Discover Anthem’s approach to addressing maternal birth equity disparities through a successful multi-sector partnership approach.

Learn about Anthem’s Doula Pilot Program in California, including program details such as building community partnerships, innovative payment structures and a review of outcomes.

Hear from a community partner about the value of working directly with a health plan and learn how to get involved locally.

Understand how Anthem is influencing and supporting policy development relating to doula services.

Webinars